Eli Lilly reported a 47.67% revenue increase to $22.974 billion, driven by strong sales of Mounjaro at nearly $10 billion. Despite price pressures and higher tax rates, the company raised its full-year guidance, reflecting confidence in growth. Analysts see potential for the stock to rise to $1,750 by 2027, fueled by upcoming drug approvals and global launches, though risks remain from competitive pressures and regulatory outcomes.
Eli Lilly has solidified its dominance in the global obesity drug market, maintaining a 60-61% market share in the US despite rising competition and pricing challenges. The company continues to grow through increasing prescriptions and expanding glob...
The Vanguard Growth ETF (VUG) charges a very low fee of 0.03%, costing about $3 annually on a $10,000 investment. However, the real risk lies in its heavy concentration, with over 65% of the fund invested in just ten large-cap stocks like NVIDIA, App...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
Eli Lilly became the first pharmaceutical company valued over $1 trillion, driven by strong revenue growth and promising drugs like retatrutide and orforglipron. The company reported a 47.67% revenue increase in Q2 and raised its 2026 revenue guidanc...
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
